about
Treating refractory leukemias in childhood, role of clofarabineMolecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemiaOutcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trialToxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.Combination therapeutics of Nilotinib and radiation in acute lymphoblastic leukemia as an effective method against drug-resistanceA therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALLPharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemiaA phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia.Incidence of common preleukemic gene fusions in umbilical cord blood in Slovak population.Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.The Prevalence of fungal infections in children with hematologic malignancy in Ali-Asghar Children Hospital between 2005 and 2010.Improving access to novel agents for childhood leukemia.CD22ΔE12 as a molecular target for RNAi therapy.Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.Outcomes after induction failure in childhood acute lymphoblastic leukemia.Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemiaExcellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocolIncidence and risk factors for central nervous system relapse in children and adolescents with acute lymphoblastic leukemia.Cellular therapies in acute lymphoblastic leukemiaNovel Bruton's tyrosine kinase inhibitors currently in development.French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia.Clofarabine for the treatment of acute lymphoblastic leukemia.Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemiaAsparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.Clinical potential of targeting Bruton's tyrosine kinase.Butein inhibits cell proliferation and induces cell cycle arrest in acute lymphoblastic leukemia via FOXO3a/p27kip1 pathwayChemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]Analysis of outcomes and prognostic factors of acute lymphoblastic leukemia patients treated by MCP841 protocol: A regional cancer center experience.Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donorsPhosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.Antibody therapy for pediatric leukemia.
P2860
Q24647279-B57ECE50-86C6-41F4-B7DD-47E820101637Q24657303-6BB4D14B-9EF6-45AC-90B4-411035B557A3Q33628794-03A92474-F01A-45DA-9888-B552ED5F10AFQ33637143-59ABC1D6-A3D9-48E4-A15B-81275F2B29FAQ33732575-B28F8CBE-0FDE-444C-B071-1BC685C27F0DQ33801811-24C3C48F-8A9E-46AA-83B1-DA7A1800DE35Q33879498-DA437D26-B46C-4704-8E77-9876E5F30AEFQ34052660-2DEB3AB2-69C0-4F09-82C0-89313E73A208Q34217173-35AC5511-7E88-4048-8C18-7369124D80E0Q34221738-F024156F-3A63-405A-80A0-764C58E56A2BQ34557915-2AFAB79C-20B0-4950-B031-7BD464A9CDDDQ35061729-8189B7A2-C8C4-47E5-B4A0-446EB4946D44Q35070594-2262DBB7-2239-44ED-A50D-5FBDB947D001Q35118597-0FC6CB79-FA60-4EC8-8B17-BAF57FC24C22Q35183874-28A52491-A310-4142-88A6-84755B7E0FC7Q35470678-C37E36FE-53B3-4E96-842C-ED1D6D9449AFQ35688742-8CB381BA-A7DC-4052-96B0-44162AFEB2C2Q35801180-2599C92F-F54A-48D7-8849-B555774A54CAQ35848913-07823DA4-2D42-4A67-8E10-F38A51D14AB7Q36029619-907E033D-A790-4411-9065-EA054988444FQ36194829-85CE7DB7-EE80-4FDC-A360-C2CD74974B41Q36366644-DA0AF847-7B63-427F-B352-838E0770B5D9Q36534036-52E000BE-D280-4C07-AF24-09E348F40F7FQ36552098-FD88DBBC-8613-4529-AB99-A87B9D84C919Q36673755-211AB591-7ADA-4D24-B6A7-02DAE5258C87Q36689775-98F85473-9AD0-4F2A-AAF8-B9AE3565C012Q36731404-79BF0FCD-0467-4D3E-A53C-ADEB59EBBF0CQ36873283-CF7EB1AE-9E7C-4AB3-86EE-44129AC3CB6AQ36918761-4E75FC42-9728-409D-9428-BE55B6A665D7Q36969782-90629C25-8ECB-4587-9A1B-A79433547541Q37094690-A61A92A8-E403-461A-AAD2-09EB39B498F6Q37109845-086FE3A6-EE83-482F-B439-9AD8000E09E0Q37126126-1F0CD758-F117-4532-8DBE-B643C9B4987BQ37296134-9B5AFE10-70BE-44CC-8CAB-74DE91F8BFB6Q37331114-C924F025-1F50-406C-9704-C488C019DAD7Q37436345-AF64EEA0-16C5-4F7A-B4C8-456D0A0F9E28Q37579597-41189533-D5DE-49BF-9351-570B79975D17Q37675273-59315778-B225-4E7E-A7A2-7890AF5BBBDCQ37677743-9673B0A8-8B55-4003-815B-3F3F821272E3Q37725578-2732BB24-2452-474E-8E6E-DEC7415673A8
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Childhood acute lymphoblastic leukaemia and relapse.
@ast
Childhood acute lymphoblastic leukaemia and relapse.
@en
type
label
Childhood acute lymphoblastic leukaemia and relapse.
@ast
Childhood acute lymphoblastic leukaemia and relapse.
@en
prefLabel
Childhood acute lymphoblastic leukaemia and relapse.
@ast
Childhood acute lymphoblastic leukaemia and relapse.
@en
P2860
P1476
Childhood acute lymphoblastic leukaemia and relapse.
@en
P2860
P304
P356
10.1111/J.1365-2141.2005.05773.X
P407
P577
2005-12-01T00:00:00Z